Caroline Jacquet

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Éric Durot, Lukshe Kanagaratnam, Sylvain Choquet, Pierre Sesques et autres

Abstract Introduction: The prognosis of patients (pts) with histological transformation (HT) of Waldenström macroglobulinemia (WM) remains dismal with standard chemoimmunotherapy. CD19-targeted chimeric antigen receptor T-cell therapies (CAR-T) can lead to durable responses in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) and are approved …

fr, us, it, gb (code pays fourni par la source)

Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine

Sylvain Lamure, Houria Hendel Chavez, Marie-Ghislaine de Goër de Herve, Luc‐Matthieu Fornecker et autres

Due to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma …

fr (code pays fourni par la source)

Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg

Franck Touret, Guillaume Martin‐Blondel, Xavier Nicolas de Lamballerie, Axelle Dupont et autres

fr (code pays fourni par la source)

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation

Xavier Nicolas de Lamballerie, Guillaume Martin‐Blondel, Axelle Dupont, Jacques Izopet et autres

fr (code pays fourni par la source)